This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Anthony Wilkinson
I am a Registered Foreign Lawyer in the Intellectual Property Group, based in our Hong Kong office. As a registered medical practitioner, pharmacist and lawyer, with extensive experience in the global medical industry, I bring a unique background to advise our clients on a broad range of matters in the life sciences space. Outside of my knowledge of hospital medicine, I have a strong background in the regulation and marketing requirements of medicines and devices. I have worked as a Medical Officer (Prescription Medicine) for a government regulator, as well as the Head of Clinical Review for a major European Notified Body. My work in the medical industry has seen me responsible for a range of areas including: medical affairs, government affairs, corporate compliance, business management, regulatory affairs, technology acquisition, reimbursement and clinical affairs.
I have spent the last decade living and working for medical companies in Australia, the USA and Hong Kong. I have handled medical product registrations across all major regulated jurisdictions, and I have a deep understanding of the needs of international life sciences clients. I have a specific interest in medical product regulation and understand the increasingly complex regulatory landscape for these products.
I look to advise our clients in a number of life sciences areas including IP issues, regulatory issues, marketing authorisations, as well as clinical trial and R&D agreements.
2
Articles
0
Comments
Chinese patent linkage system – the Chinese Supreme Court issues Draft Judicial Interpretations
The Chinese Supreme Court (“SPC”) released on 29 October 2020 the “Provisions on Several...
November 13, 2020
6 min read
The US/China Trade Agreement: what could it mean for the Pharma Industry?
Following a long period of negotiation, Phase I of the US-China Trade Agreement was published on 15 January...
February 6, 2020
5 min read